Acellular Dermal Matrix–assisted Implant-based Breast Reconstruction: Surgical and Patient-reported Outcomes From the Mastectomy Reconstruction Outcomes Consortium Study Authors: Christian X. Lava, Karen R. Li, Qian Mao, Renata S. Magalhaes, Heather Portaro, Yi Duan-Arnold, Kenneth L. Fan Published: 2026 ABSTRACT Background:Acellular dermal matrices (ADMs) are used in most of the United States but are not FDA-approved for this indication. We evaluated SurgiMend (Integra) in immediate 2-stage subpectoral reconstruction versus no ADM.Methods:An FDA-aligned statistical analysis plan was applied to the prospective Mastectomy Reconstruction Outcomes Consortium cohort. Patients underwent 2-stage subpectoral implant-based breast reconstruction with SurgiMend or without ADM. BREAST-Q Physical Well-Being (Chest) scores were collected preoperatively and at 1 week, 3 months, 1 year, and 2 years. The primary outcome was composite clinical success, defined as a decline in BREAST-Q score of 4 point or less at 1 year and no major complication within 2 years.Results:Among 987 patients, 119 (12.1%) received SurgiMend and 868 (87.9%) underwent reconstruction without ADM. Mean age was 48.1±10.4 years. Mean body mass index was 25.8±5.3 kg/m2. Most patients underwent mastectomy for cancer (SurgiMend 85.7%; control 92.9%); nearly half underwent prophylactic procedures (SurgiMend 47.9%; control 52.9%). At 1 year, BREAST-Q scores were higher in the SurgiMend group (44.5% versus 39.1%; difference 5.4%, 95% CI −5.2 to 16.0). In propensity-adjusted analyses, major complications were lower with SurgiMend (33.7% versus 46.7%; difference −13.1%, 95% CI −22.5 to −3.7). Composite clinical success was significantly higher with SurgiMend (32.4% versus 21.1%; difference 11.2%, 95% CI 1.7 to 20.8; P = 0.02).Conclusions:SurgiMend was associated with fewer complications and higher patient-reported outcomes, supporting its safety and effectiveness in postmastectomy reconstruction. Takeaways Question: What is the safety and effectiveness of SurgiMend, a fetal bovine acellular dermal matrix, in immediate 2-stage, subpectoral implant-based breast reconstruction compared with no acellular dermal matrix? Findings: Using a prespecified statistical analysis plan with Food and Drug Administration input, we retrospectively analyzed 987 patients from the prospective Mastectomy Reconstruction Outcomes Consortium study. SurgiMend patients had fewer major complications (33.7% versus 46.7%) and significantly higher composite clinical success (32.4% versus 21.1%), with improved BREAST-Q physical well-being scores. Meaning: SurgiMend demonstrated improved safety and patient-reported outcomes, supporting its use as effective soft-tissue support in implant-based breast reconstruction. INTRODUCTION Breast cancer remains a major global health concern, with more than 2 million new cases diagnosed annually. In the United States, about 310,000 new cases were expected in 2024.1 Increasingly, women undergo breast reconstruction following mastectomy for treatment or prophylaxis.2 Implant-based breast reconstruction (IBR) is now the most common technique.3 IBR has been shown to improve body image, sexuality, and quality of life.4,5 In 2022, the American Society of Plastic Surgeons reported that approximately 65% of IBR procedures in the United States used acellular dermal matrices (ADMs), recognizing ADM use as a standard of care.6 ADMs provide soft-tissue support and allow greater initial fill volumes and improved shaping.7 However, some studies noted increased risks of infection, seroma, and total reconstructive failures.8–10 Despite the ubiquity of ADM use in IBR, none are approved by the Food and Drug Administration (FDA) specifically for breast reconstruction. Using the Mastectomy Reconstruction Outcomes Consortium (MROC) study dataset, this study compared SurgiMend PRS acellular bovine dermal matrix (SurgiMend PRS ABDM) with no ADM in immediate, 2-stage, subpectoral IBR. METHODS Study Design A prespecified analysis of MROC participants undergoing immediate, 2-stage subpectoral IBR was performed with existing institutional review board approvals. The MROC was a multi-institutional, prospective, observational cohort study (2012–2015, 11 sites) assessing outcomes after postmastectomy reconstruction.11,12 For this subset analysis, patients were included if they (1) were 18 years of age or older; (2) underwent immediate, 2-stage, subpectoral IBR; and (3) received SurgiMend or no ADM. Patients were categorized into the ADM (SurgiMend) group or the control group. Data Collection For this study, patient characteristics, operative details, postoperative complications, and patient-reported outcome measures (PROMs) were extracted from the MROC database. Patient characteristics included demographics and comorbidities, such as age, race, work status, marital status, education, body mass index (BMI), and smoking status. Charlson Comorbidity Index scores were calculated to quantify comorbidity burdens.13 Operative details included reasons for mastectomy (prophylactic versus therapeutic), laterality (bilateral versus unilateral mastectomy), type of mastectomy, mastectomy weight, lymph node management, implant type (silicone versus saline), and implant size (ie, final implant volume). Information on exposure to radiation and chemotherapy was also collected. Major complications included hematoma, explantation, reoperation due to complications, elective revisions, capsular contracture, infection (treated with either oral or intravenous antibiotics), dehiscence, tissue necrosis, implant rupture, and seroma. The following PROMs were collected: BREAST-Q Reconstruction module (Satisfaction with Breasts, Physical Well-Being [Chest], Psychosocial Well-Being, Sexual Well-Being, Satisfaction with Outcome, Satisfaction with Nipple Reconstruction), numerical pain rating scale (NPRS), McGill Pain Questionnaire (MPQ), European Organization for Research and Treatment of Cancer (EORTC), Brief Fatigue Inventory (BFI), Patient-Reported Outcomes Measurement Information System (PROMIS), Patient Health Questionnaire (PHQ-9), and Generalized Anxiety Disorder scale (GAD-7). Study Endpoints The primary endpoint was composite clinical success (CCS), defined as the proportion of patients who experienced both (1) absence of major complications through the second postoperative year and (2) a BREAST-Q Physical Well-Being (Chest) module score that was no more than 4 points lower at 1 year after surgery compared with the preoperative baseline score.14,15 The minimally important difference for the BREAST-Q Physical Well-being (Chest) domain is 4 points.16 The objective of this composite endpoint was to focus on the patient experience by capturing both major postoperative complications and the patient’s perspective of physical well-being following IBR. Secondary endpoints assessed change from baseline at each follow-up time point between the 2 groups for BREAST-Q, NPRS, MPQ, EORTC, BFI, PROMIS, PHQ-9, and GAD-7. Patients completed PROMs preoperatievely and at 1 week, 3 months, 1 year, and 2 years after initial surgery. Statistical Analysis Group comparisons used unpaired 2-tailed t tests or Mann-Whitney tests, as appropriate. Categorical variables were compared using Pearson χ2 or Fisher exact tests (n < 7). Multiple logistic regression included significant covariates and known predictors, excluding variables with perfect prediction or collinearity. A propensity score (PS) model was used for the primary endpoint analysis. The PS model was fitted using logistic regression, with treatment modality as the outcome and baseline covariates including age, race, BMI, work status, marital status, Charlson Comorbidity Index, smoking status, indication, mastectomy reason, laterality, mastectomy type, implant type and size, lymph node management, and radiation or chemotherapy. Five strata were created based on PS quantiles. Because SurgiMend cases were limited to 2 sites, group sizes were unbalanced. Outcomes were compared within strata, and a common treatment effect was derived by weighting stratum-specific estimates. Point estimates and 95% confidence intervals (CIs) were calculated. Superiority of SurgiMend versus no ADM was evaluated using a PS-stratified Z test (2-sided P = 0.05). Robustness was assessed by excluding infections treated with oral antibiotics only or elective revisions from the definition of major complications, given inconsistent reporting across sites. Secondary endpoints were summarized by visit. Analysis of covariance for change from baseline, stratified by PS, was used to analyze function scores. The proportion of subjects with a decrease of 4 points or less from baseline for the BREAST-Q modules was summarized with point estimates and 95% CIs. No multiplicity adjustments were applied. Safety outcomes were summarized descriptively. Analyses were performed using StataBE (StataCorp LLC, College Station, TX), with a P value less than 0.05 considered significant. RESULTS Patient Characteristics and Operative Details A total of 987 patients (1580 breasts) were included in the analysis, comprising 119 patients (12.1%; n = 179 breasts [11.3%]) in the SurgiMend group and 868 (87.9%; n = 1401 breasts [88.7%]) in the control group. The mean age was 48.1 ± 10.4 years. The mean BMI was 25.8 ± 5.3 kg/m2. The mean implant size per breast was 462.6 ± 158.1 and 496.4 ± 155.9 mL for the SurgiMend and control groups, respectively. No statistically significant differences were observed between the SurgiMend and control groups for any baseline demographic or operative variables (all P > 0.05). Patient characteristics and operative details of the cohorts are presented in Table 1 and Supplemental Digital Content 1. (See table, Supplemental Digital Content 1, which displays baseline demographic, clinical, and operative characteristics of the full analysis set [per breast] [A], summary of BREAST-Q domain scores at baseline, year 1, and year 2 following breast reconstruction [B], summary of continuous change from baseline in BREAST-Q domain scores [C], summary of continuous change from baseline in NPRS and MPQ scores [D], summary of change from baseline in PROMIS domain scores [E], summary of continuous change from baseline in EORTC functional scale scores [F], and BFI, anxiety and depression (PHQ-9), and GAD-7 scale for anxiety and depression—change from baseline [G], https://links.lww.com/PRSGO/E864.) Table 1.Baseline Demographic, Clinical, and Operative Characteristics of the FAS (per Patient)CharacteristicSurgiMendControlTotalN = 119N = 868N = 987Age, y Mean (SD)49.7 (11.1)47.9 (10.3)48.1 (10.4) Min, max28, 7820, 7720, 78Body mass index, kg/m2 Mean (SD)25.7 (5.3)25.8 (5.3)25.8 (5.3) Min, max16.8, 43.816.5, 49.816.5, 49.8Smoking, n (%) Never smoked86 (72.3)540 (62.2)626 (63.4) Current/previous smoker32 (26.9)308 (35.5)340 (34.4)Race, n (%) White99 (83.2)738 (85.0)837 (84.8) Other17 (14.3)109 (12.6)126 (12.8)Work status, n (%) Employed full-time59 (49.6)455 (52.4)514 (52.1) Employed part-time16 (13.4)118 (13.6)134 (13.6) Homemaker23 (19.3)126 (14.5)149 (15.1) Retired11 (9.2)58 (6.7)69 (7.0) Other9 (7.6)86 (9.9)95 (9.6)Marital status, n (%) Married96 (80.7)639 (73.6)735 (74.5) Other (widowed, separated, divorced, single/never married)22 (18.5)209 (24.1)231 (23.4)Education, n (%) Some high school; high school diploma; or some college, trade, or university24 (20.2)180 (20.7)204 (20.7) College, trade, or university51 (42.9)333 (38.4)384 (38.9) Some graduate study with/without master’s/doctoral degree43 (36.1)338 (38.9)381 (38.6)Laterality, n (%) Unilateral59 (49.6)335 (38.6)394 (39.9) Bilateral60 (50.4)533 (61.4)593 (60.1)Breast cancer treatment, n (%) Yes102 (85.7)806 (92.9)908 (92.0) No17 (14.3)62 (7.1)79 (8.0)Breast cancer prophylaxis, n (%) Yes57 (47.9)459 (52.9)516 (52.3) No62 (52.1)409 (47.1)471 (47.7)SLNB, n (%) Yes67 (56.3)493 (56.8)560 (56.7) No52 (43.7)375 (43.2)427 (43.3)ALND with or without SLNB, n (%) Yes29 (24.4)290 (33.4)319 (32.3) No90 (75.6)578 (66.6)668 (67.7)Type of mastectomy, n (%) Nipple sparing13 (10.9)105 (12.1)118 (12.0) Simple or modified radical mastectomy106 (89.1)763 (87.9)869 (88.0)Neoadjuvant chemotherapy, n (%) Yes27 (22.7)131 (15.1)158 (16.0) No92 (77.3)737 (84.9)829 (84.0)Adjuvant chemotherapy, n (%) Yes24 (20.2)305 (35.1)329 (33.3) No95 (79.8)563 (64.9)658 (66.7)Radiation, n (%) Yes29 (24.4)227 (26.2)256 (25.9) No89 (74.8)621 (71.5)710 (71.9)Charlson index, n (%) ≤193 (78.2)684 (78.8)777 (78.7) >126 (21.8)172 (19.8)198 (20.1)Subjects with missing values were not included. For categorical variables, all percentages were calculated using the following denominators: SurgiMend = 119, control = 868, and total = 987.ALND, axillary lymph node dissection; FAS, full analysis set; SLNB, sentinel lymph node biopsy. Baseline Demographic, Clinical, and Operative Characteristics of the FAS (per Patient) Subjects with missing values were not included. For categorical variables, all percentages were calculated using the following denominators: SurgiMend = 119, control = 868, and total = 987. ALND, axillary lymph node dissection; FAS, full analysis set; SLNB, sentinel lymph node biopsy. Primary Endpoint Analysis In the prespecified PS-adjusted analysis, a significantly higher proportion of patients achieved CCS in the SurgiMend group than in the control group (32.4% versus 21.1%, respectively; difference 11.2%, 95% CI 1.7%–20.8%; P = 0.02) (Table 2). Multiple sensitivity analyses showed directionally consistent results. When infections treated with oral antibiotics only were excluded from the definition of major complications, a higher proportion of SurgiMend patients achieved CCS compared with control patients (32.4% versus 21.6%; difference 10.7%, 95% CI 1.1%–20.3%) (Table 3). When elective revisions were excluded, CCS rates were 38.3% versus 29.7% (difference 8.6%, 95% CI −1.6% to 18.8%). When both were excluded, CCS rates were 40.0% versus 31.5% (difference 8.4%, 95% CI −1.8% to 18.7%) (Table 4). The higher revision rate among SurgiMend patients largely reflected elective aesthetic revisions, which were conservatively classified as major complications. In the PS-adjusted analysis, a greater proportion of SurgiMend patients regained baseline BREAST-Q Physical Well-Being (Chest) scores at 1 year compared with controls (44.5% versus 39.1%; difference 5.4%, 95% CI −5.2% to 16.0%) (Table 5). Table 2.Unadjusted (Observed) and PS-adjusted Estimates for the Primary EndpointUnadjusted EstimatesPS-adjusted Estimates (ATT)SurgiMend (n = 119)Control (n = 868)Difference (SurgiMend: No ADM Control) (95% CI)SurgiMend (n = 119)Control (n = 868)Difference (SurgiMend: No ADM Control)(95% CI)32.3%22.4%9.9% (0.5%–19.3%)32.4%21.1%11.2% (1.7%–20.8%)P = 0.02ATT, average treatment effect of the treatment. Unadjusted (Observed) and PS-adjusted Estimates for the Primary Endpoint ATT, average treatment effect of the treatment. Table 3.Unadjusted (Observed) and PS-adjusted Estimates for the Primary Endpoint Sensitivity Analysis of the CCS in Which Wound Infection Requiring Oral Antibiotics Was Not Considered a Major ComplicationUnadjusted (Observed) EstimatesPS-adjusted Estimates (ATT)SurgiMend (n = 119)Control (n = 868)Difference (SurgiMend: No ADM Control)(95% CI)SurgiMend (n = 119)Control (n = 868)Difference (SurgiMend: No ADM Control)(95% CI)32.3%22.8%9.6% (0.2%–19.0%)32.4%21.6%10.7% (1.1%–20.3%)ATT, average treatment effect of the treatment. Unadjusted (Observed) and PS-adjusted Estimates for the Primary Endpoint Sensitivity Analysis of the CCS in Which Wound Infection Requiring Oral Antibiotics Was Not Considered a Major Complication ATT, average treatment effect of the treatment. Table 4.Unadjusted (Observed) and PS-adjusted Estimates for the Primary Endpoint Sensitivity Analysis in Which Elective Revisions and Wound Infection Requiring Oral Antibiotics Were Not Considered Major ComplicationsUnadjusted EstimatesPS-adjusted Estimates (ATT)SurgiMend (n = 119)Control (n = 868)Difference (SurgiMend: No ADM Control)(95% CI)SurgiMend (n = 119)Control (n = 868)Difference (SurgiMend: No ADM Control)(95% CI)40.0%32.3%7.6% (−2.3% to 17.6%)40.0%31.5%8.4% (−1.8% to 18.7%)ATT, average treatment effect of the treatment. Unadjusted (Observed) and PS-adjusted Estimates for the Primary Endpoint Sensitivity Analysis in Which Elective Revisions and Wound Infection Requiring Oral Antibiotics Were Not Considered Major Complications ATT, average treatment effect of the treatment. Table 5.Subjects’ Success Rate in BREAST-Q Physical Well-Being (Chest) at 1 Year PostreconstructionUnadjusted EstimatesPS-adjusted Estimates (ATT)SurgiMend (n = 119)Control (n = 868)Difference (SurgiMend: No ADM Control) (95% CI)SurgiMend (n = 119)Control (n = 868)Difference (95% CI)44.5%40.3%4.2% (−6.2% to 14.6%)44.5%39.1%5.4% (−5.2% to 16.0%)ATT, average treatment effect of the treatment. Subjects’ Success Rate in BREAST-Q Physical Well-Being (Chest) at 1 Year Postreconstruction ATT, average treatment effect of the treatment. Major Complications A total of 40 (33.7%) SurgiMend patients and 405 (46.7%) control patients experienced 1 or more major complications, resulting in a 13.1% lower incidence of complications for the SurgiMend group (95% CI −22.5% to −3.7%). Through 2 years of follow-up, the most frequent major complications in both groups were reoperations (SurgiMend, 29.4%; control, 37.1%), elective revision (SurgiMend, 22.7%; control, 30.8%), revision due to complications (SurgiMend, 11.8%; control, 10.6%), and explantation due to complications (SurgiMend, 9.2%; control, 8.1%) (Table 6). Table 6.Postoperative Complications in the SurgiMend Cohort or No-ADM Control Cohort Through Year 2ComplicationPostoperative Year 1Postoperative Year 2Major Complications up to Postoperative 2 Years+SurgiMend, n (%)Control, n (%)Difference, %SurgiMend, n (%)Control, n (%)Difference, %SurgiMend, n (%)Control, n (%)Difference, %Any major complication38 (31.9)342 (39.4)−7.5§−7.540 (33.6)405 (46.7)−13.1Any major complication excluding elective revisions and wound infection requiring oral antibiotics21 (17.7)172 (19.8)−2.1§21 (17.7)201 (23.2)−5.5Hematoma§−1.5§§−0.3§−1.8Explantation (including elective revisions)14 (11.8)82 (9.5)2.3§−2.116 (13.5)106 (12.2)1.3 Removal due to complications11 (9.2)59 (6.8)2.4§−1.911 (9.2)70 (8.1)1.1 Elective removal§−0.3§−0.5−0.6Capsular contracture§§−0.5§−1.6§−1.8 Local moderate to severe capsular contracture§§−0.5§−1.6§−1.8 Revision procedure due to capsular contracture c§§−0.1§−0.1§§−0.2Infection§−4.2§§−1.1§−4.8 Wound infection requiring oral antibiotics§−2.7§§−0.4§−3.0 Wound infection requiring intravenous antibiotics§−1.3§§−0.5§−1.7 Wound infection requiring surgical or percutaneous drainage of abscess§0.4§§−0.1§0.3Dehiscence§−1.4§§−0.1§−1.5Implant leakage, rupture, and/or deflation§§0.2§§−0.1§§0.1Seroma§0.6§§−0.4§0.4Tissue necrosis§−1.5§§0§−1.5 Local tissue necrosis§−1.0§§0§−1.0 Revision procedure due to necrosis§1.1§§0§1.1Reoperation (including elective revisions)33 (27.7)256 (29.5)−1.8§−6.535 (29.4)322 (37.1)−7.7Reoperation (excluding elective revisions)14 (11.8)74 (8.5)3.3§3.114 (11.8)94 (10.8)1.0 Implant malposition requiring surgical correction§−0.1§§−0.4§§−0.5 Secondary attempt at reconstruction§1.8§−0.4§1.3 Revisions due to complications14 (11.8)74 (8.5)3.3§3.414 (11.8)92 (10.6)1.2 Elective revisions22 (18.5)202 (23.3)−4.8§−4.827 (22.7)267 (30.8)−8.1Death§§02§§0.7§§0.2+Twenty-one subjects (20 control and 1 SurgiMend) with no complications during the 2-year postoperative period were counted as having no major complications.§Cells a subject count 10 or less were not reported in accordance with NIH and CMS. Postoperative Complications in the SurgiMend Cohort or No-ADM Control Cohort Through Year 2 Twenty-one subjects (20 control and 1 SurgiMend) with no complications during the 2-year postoperative period were counted as having no major complications. Cells a subject count 10 or less were not reported in accordance with NIH and CMS. Secondary Endpoint Analyses: PROMs A summary of BREAST-Q domain scores at baseline, 1 year, and 2 years is provided in Supplemental Digital Content 1 (https://links.lww.com/PRSGO/E864). Decreases in BREAST-Q physical, psychosocial, and sexual well-being were greatest at 3 months, then improved by 1–2 years in both groups (Supplemental Digital Content 1, (https://links.lww.com/PRSGO/E864). For the NRPS, changes from baseline peaked at 1 week (SurgiMend, 3.0; control, 2.9; difference 0.1, 95% CI −0.5 to 0.5) and decreased by 3 months (SurgiMend, 0.6; control, 1.1; difference −0.6, 95% CI −1.0 to −0.1). Changes remained low at 1 and 2 years. The MPQ followed similar patterns at 1 week (SurgiMend, 9.3; control, 8.9; difference 0.4, 95% CI −1.4 to 2.3) and 3 months (SurgiMend, 1.9; control, 3.0; difference −1.1, 95% CI −2.8 to 0.5) (Supplemental Digital Content 1, https://links.lww.com/PRSGO/E864). PROMIS outcomes were generally consistent between groups: anxiety improved at 3 months (SurgiMend, −8.6; control, −7.4; difference −1.2, 95% CI −3.1 to 0.8), with benefits sustained to 2 years. PROMIS physical function decreased at 3 months, then improved at 1–2 years without fully returning to baseline (Supplemental Digital Content 1, https://links.lww.com/PRSGO/E864). Regarding the EORTC measures, body image improved versus baseline at all time points. Breast symptoms peaked at 3 months (SurgiMend, 7.2; control, 5.8; difference 1.4, 95% CI −2.8 to 5.6), and were low at 1–2 years. Most other domains worsened at 3 months and improved thereafter. Future prospective remained lower than baseline in both groups (Supplemental Digital Content 1, https://links.lww.com/PRSGO/E864). BFI, PHQ-9, and GAD-7 were generally comparable between groups (Supplemental Digital Content 1, https://links.lww.com/PRSGO/E864). The receiver operating characteristic curve analysis yielded an area under the curve of 0.6 or greater, indicating at least modest discrimination across all logistic regression models. DISCUSSION Using data from the MROC study, we determined that SurgiMend demonstrated both safety and effectiveness as a soft-tissue support in immediate, 2-stage, subpectoral, alloplastic breast reconstruction following mastectomy. Specifically, SurgiMend provided significant benefits, as evidenced by superior CCS compared with the control group. During the past 2 decades, ADMs have become an important component in postmastectomy IBR, despite lacking an FDA-approved indication.17,18 In our study, the ADM of interest, SurgiMend, met prespecified CCS criteria, defined as (1) return to baseline within 1 year after surgery, according to the BREAST-Q Physical Well-Being (Chest) module, and (2) absence of major complications for 2 years postoperatively. In the PS-matched analysis, 32% of patients who underwent IBR with SurgiMend met the criteria for CSS, compared with 21% in the control group. This 11% improvement, observed across 119 IBRs with SurgiMend, suggests that SurgiMend may improve PROMs and decrease the risk of complications compared with reconstructions performed without ADM. Furthermore, the SurgiMend group experienced a lower incidence of major complications compared with the control group (33.6% versus 46.7%, respectively), highlighting a benefit of using SurgiMend for IBR. Notably, recent advances in digital technology are changing how outcomes are measured in reconstructive surgery. Three-dimensional surface imaging, virtual wound morphometry, and mobile applications allow quantitative evaluation of breast contour and scar quality. When combined with validated PROMs such as BREAST-Q, SCAR-Q, and BODY-Q, they offer a multidimensional understanding of functional and aesthetic recovery in ADM-assisted reconstruction.19,20 It has been suggested that the potential trade-off for the benefits of using ADMs in breast reconstruction may be an increased rate of complications; however, in our analysis, the absolute rates of complications for the PS-adjusted populations were 33.6% for IBR using SurgiMend and 46.7% for those without ADM, resulting in a 13.1% reduction in complications for the SurgiMend group (95% CI: −22.5% to −3.7%). Excluding elective revisions and wound infections treated with oral antibiotics, the rates were 17.7% for SurgiMend and 23.2% for the control group, with SurgiMend showing a 5.5% lower incidence of complications (95% CI: −12.5% to 2.7%). These findings indicate that complications with SurgiMend were lower than those without ADM, challenging earlier studies suggesting a comparable risk of complications with the use of ADM.21,22 In 1 study using data from MROC, Sorkin et al23 observed a trend toward higher risks of major complications and reconstructive failure with ADM compared with no ADM. Similarly, Ganesh Kumar et al24 reported a significantly higher risk of major complications with ADM use compared with no ADM (22.9% versus 16.4%; P = 0.04), although ADM brands were not distinguished in these studies, and there remained no differences in terms of infection, reconstructive failure, flap necrosis, capsular contracture, seroma, hematoma, implant malposition, or implant rupture. A recent, brand-specific analysis from MROC identified a higher risk of complications, such as infection, implant removal, and reoperation, in patients with FlexHD (MTF Biologics) and AlloMax (Bard Davol) compared with no ADM, SurgiMend, and AlloDerm (Allergan/AbbVie) 2 years following surgery.25 Although this study focused on immediate, 2-stage subpectoral reconstruction, reconstructive techniques continue to evolve. Autologous flaps such as deep inferior epigastric perforator and transverse rectus abdominis myocutaneous flaps offer long-term durability, but require longer recovery and donor-site morbidity, whereas prepectoral ADM-based approaches may reduce animation deformity and discomfort. A systematic review of 27 studies found that 1-stage permanent expander reconstruction carries higher complication rates and a greater need for additional procedures to achieve aesthetic results comparable to 2-stage techniques, despite similar overall cosmetic outcomes.26 These findings provide historical context and a benchmark for comparison as reconstructive paradigms shift toward prepectoral approaches.27 One factor potentially contributing to the lower incidence of major complications in the SurgiMend group compared with the control group was the decreased number of elective revisions (22.7% versus 30.8%, respectively). These findings highlight the complexity of assessing ADM-related risks and the importance of factors such as patient selection and surgical techniques. In a multicenter, randomized controlled trial (RCT), Broyles et al28 found no significant difference in complications between FlexHD Pliable and AlloDerm ADMs. However, obesity and prepectoral placement were identified as independent risk factors for complications.28 The choice of ADM type, such as SurgiMend, could also contribute to lower complication rates compared with IBR without an ADM.29,30 SurgiMend is derived from fetal bovine dermis, rich in type I and type III collagen, with relatively low levels of elastin compared with human ADM. Further, preclinical and clinical studies have shown robust cellular and vascular infiltration into the collagen structure.31,32 Its distinct source material and processing method may enhance the structural integrity of the reconstructed soft tissue and allow for faster integration within host tissue.33 Additionally, its design features “fenestrations,” which allow for fluid transfer while providing structural support, thereby supporting nutrient diffusion and neovascularization. Margulies and Salzberg34 highlighted the potential for ADM to facilitate IBR and improve aesthetic outcomes, further suggesting that the choice of ADM and meticulous patient selection are key to optimizing outcomes and minimizing risks in IBR. Regarding the BREAST-Q Physical Well-Being (Chest) module, 44.5% of SurgiMend patients and 39.1% of control patients reported a return to their perception of preoperative well-being at 1 year. The difference is 5.4% (95% CI, −5.2% to 16.0%). This aligns with prior reports showing no significant BREAST-Q differences between ADM and control groups.23,35 Pain trajectories (NPRS/MPQ) improved by 3 months and remained low through 2 years, consistent with findings reported by McCarthy et al36 and Sorkin et al.23 PROMIS showed early decline at 3 months, followed by recovery by 1–2 years and no between-group differences. EORTC domains followed a similar pattern, with transient worsening at 3 months and improvement by 1 year. These results underscore the complex relationship between physical recovery, patient satisfaction, and psychological well-being in breast reconstruction, providing insight into improved outcomes and satisfaction with the procedure. A novel aspect of this study is the incorporation of a CCS endpoint that integrated both safety outcomes and PROMs. The integration of a validated PROM into the primary endpoint provides a more holistic assessment of reconstructive success. Additionally, this study is notable for its use of real-world data from the MROC study dataset. The focus on immediate 2-stage subpectoral reconstruction reflects both the clinical standard during the MROC enrollment period (2012–2016) and the specific FDA indication for SurgiMend PRS ABDM. DTI and prepectoral approaches were still emerging then, making a subpectoral cohort the most representative population for evaluating safety and effectiveness. Traditionally, premarket approval requires an investigational device exemption, often necessitating an RCT. Such trials are time-consuming, costly, and increasingly impractical. The evolution of breast reconstruction practices in the United States has rendered RCTs with a no-ADM control arm infeasible for subpectoral reconstruction. For instance, some trials have been prematurely terminated due to difficulties in patient enrollment.37 In this study, the sponsor used real-world data from the MROC study—a prospective, multicenter, multisurgeon study designed to evaluate different surgical approaches to breast reconstruction—while developing a statistical analysis plan to compare SurgiMend with no ADM use. Importantly, the sponsor remained blinded to the MROC outcomes during this process. The FDA subsequently conducted the data analysis based on the statistical analysis plan and provided the final analysis report. Collaborations between industry and regulatory bodies such as the FDA can strengthen the medical device ecosystem by ensuring that new indications are rigorously evaluated, leveraging real-world data to complement traditional evidence-generation approaches. This approach also helps protect patients from ineffective or unsafe technologies while leveraging advancements in real-world data to generate robust and actionable evidence in a cost-effective and efficient manner. Postoperative care also remains a key determinant of reconstructive outcomes. Consistent wound surveillance and dressing choice can affect healing trajectories following ADM-assisted IBR. Recent evidence suggests that interactive dressings with moisture regulation and embedded sensors enhance early evaluation and patient comfort compared with traditional coverings. Integrating such standardized postoperative protocols could further reduce variability and optimize healing outcomes.38,39 Limitations There are limitations to this analysis, as it is based on real-world data from a prospective observational cohort study rather than data from an RCT comparing IBR with SurgiMend to those without ADM use. First, patient selection bias is a risk in observational studies, as the surgeon’s decision to use ADM at the time of index surgery may be influenced by patient characteristics, breast anatomy, cost, and patient preferences. Nonetheless, a PS-adjusted analysis based on a prespecified statistical analysis plan was performed to mitigate this bias. The dataset also had inherent limitations regarding missing information—approximately 25% overall, with 35% missing in the SurgiMend group and 44% in the control group. The smaller SurgiMend cohort limited power for some secondary endpoints, possibly explaining the lack of statistical significance in certain analyses. Furthermore, the study’s focus on immediate, 2-stage subpectoral IBR using SurgMend limits the findings to this specific surgical approach and ADM. Finally, SurgiMend subjects were limited to 2 investigational sites, and outcomes may differ across institutions in routine clinical practice. CONCLUSIONS The ultimate goal of breast reconstruction is to help restore the patient’s body image and alleviate the distress associated with mastectomy.15 In this study, the role of SurgiMend was evaluated in 2-stage, immediate, subpectoral IBR, focusing on clinical outcomes and PROMs to determine safety and effectiveness. The statistically significant higher proportion of SurgiMend subjects who met the criteria for CCS, coupled with a numerically lower complication rate, supports the favorable role of SurgiMend in IBR. These findings demonstrate the safety and effectiveness of the use of SurgiMend in immediate, 2-stage, subpectoral IBR after mastectomy for soft-tissue support in breast cancer treatment or prophylaxis. DISCLOSURES Qian Mao, Heather Portaro, and Yi Duan-Arnold are currently employed by Integra LifeSciences. Renata S. Magalhaes was an employee of Integra LifeSciences at the time the manuscript was drafted. Kenneth L. Fan is a paid consultant for Integra LifeSciences Corporation, the sponsor of this study, and was compensated for his assistance in writing this article. At the time of this publication, SurgiMend PRS ABDM for immediate, 2-stage, subpectoral tissue expander/IBR received “approvable pending good manufacturing practice” status from the FDA, which approved and closed out the clinical portion of the PMA application. However, the device will not be marketed in the United States until the good manufacturing practice manufacturing requirements are met (new facility) and premarket approval is granted. The study was funded by Integra LifeSciences. ACKNOWLEDGMENT The authors acknowledge and thank Sandra J. Berriman, Chuck Davis, and Beverly Lorell for their contributions to this project. Supplementary Material